Table 2 Cell cycle distribution analysis in i.p. tumour xenografts of LS-174T after treatment with paclitaxel and 212Pb-TCMC-trastuzumab RIT

From: 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint

  

Time point (h)

Treatment

Phase

0

6

24

48

72

96

 

G1

67.5±2.7

     
 

S

17.7±2.0

     
 

G2-M

14.8±0.7

     

Paclitaxel-212Pb-Trastuzumab

G1

 

58.9±2.9

67.9±0.2

68.2±1.4

63.9±0.1

75.8±2.7

 

S

 

17.5±3.7

7.6±0.4

6.9±0.1

6.3±0.0

5.5±0.3

 

G2-M

 

23.6±0.8

24.5±0.6

24.9±1.2

29.8±0.0

18.8±3.0

Paclitaxel-212Pb-HuIgG

G1

 

69.3±5.9

56.5±0.4

68.5±0.1

66.3±0.0

64.2±1.7

 

S

 

14.7±0.1

17.8±0.7

5.0±0.2

5.9±0.1

16.1±4.0

 

G2-M

 

16.0±5.8

25.7±0.4

26.5±0.1

27.8±0.1

19.7±2.2

Paclitaxel

G1

 

63.3±1.5

63.6±0.2

68.1±0.2

68.0±1.6

73.3±0.2

 

S

 

22.1±3.0

18.9±1.0

14.3±0.0

12.4±0.5

11.7±0.5

 

G2-M

 

14.6±1.5

17.5±0.8

17.6±0.2

19.6±1.1

15.1±0.4

212Pb-Trastuzumab

G1

 

68.6±3.8

66.9±1.3

67.7±4.0

68.1±1.3

66.6±0.7

 

S

 

14.3±5.4

5.9±0.1

6.3±1.8

7.9±0.7

3.6±0.0

 

G2-M

 

17.1±1.6

27.3±1.2

26.1±2.1

23.9±0.6

29.7±0.7

212Pb-HuIgG

G1

 

63.9±5.2

65.1±2.3

64.6±

67.1±0.5

63.1±0.3

 

S

 

20.0±5.3

7.4±1.3

5.8±

5.5±0.1

7.8±0.7

 

G2-M

 

16.0±0.1

27.5±1.0

29.6±

27.4±0.6

29.1±1.0

  1. Abbreviation: RIT=radioimmunotherapy.
  2. Mice bearing i.p. LS-174T xenografts were pretreated with paclitaxel before 212Pb-TCMC-trastuzumab RIT. Additional groups included untreated, paclitaxel alone, 212Pb-TCMC-trastuzumab without paclitaxel pretreatment and 212Pb-TCMC-HuIgG with/without paclitaxel pre-treatment. Results represent the average of a minimum of three replications (±s.d.).
Back to article page